| Investor | Caligan Partners LP |
| Manager | David Johnson |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Caligan Partners LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | 13G | SABS / SAB Biotherapeutics, Inc. | 7,967,207 | |||||
| 2026-05-15 | 13G | IRD / Opus Genetics, Inc. | 6,075,028 | |||||
| 2026-05-15 | 13G | LBRX / LB Pharmaceuticals Inc | 1,438,070 | |||||
| 2026-05-15 | 13G/A | AVTX / Avalo Therapeutics, Inc. | 881,533 | 1,635,023 | ||||
| 2026-05-15 | 13G | SNSE / Sensei Biotherapeutics, Inc. | 126,002 | |||||
| 2026-02-17 | 13G/A | AVTX / Avalo Therapeutics, Inc. | 833,333 | 881,533 | ||||
| 2026-02-17 | 13G/A | EOLS / Evolus, Inc. | 4,138,943 | 0 | ||||
| 2026-01-27 | 13D/A | ANIK / Anika Therapeutics, Inc. | 1,435,130 | 1,435,130 | ||||
| 2025-12-30 | 13D/A | VRCA / Verrica Pharmaceuticals Inc. | 6,503,054 | 6,503,054 | ||||
| 2025-11-24 | 13D | VRCA / Verrica Pharmaceuticals Inc. | 15,856,653 | 6,503,054 | ||||
| 2025-11-21 | 13D/A | ANIK / Anika Therapeutics, Inc. | 1,435,993 | 1,435,130 | ||||
| 2025-11-14 | 13G/A | YMAB / Y-mAbs Therapeutics, Inc. | 2,342,609 | 0 | ||||
| 2025-11-14 | 13G | AVTX / Avalo Therapeutics, Inc. | 833,333 | |||||
| 2025-11-14 | 13G/A | EOLS / Evolus, Inc. | 3,341,970 | 4,138,943 | ||||
| 2025-08-14 | 13G | EOLS / Evolus, Inc. | 3,341,970 | |||||
| 2025-05-14 | 13G | YMAB / Y-mAbs Therapeutics, Inc. | 2,342,609 | |||||
| 2025-02-12 | 13G | VRCA / Verrica Pharmaceuticals Inc. | 15,856,653 | |||||
| 2024-09-18 | 13D/A | ALIM / Alimera Sciences, Inc. | 17,635,154 | 0 | ||||
| 2024-09-12 | 13D/A | LQDA / Liquidia Corporation | 6,994,997 | 8,118,592 | ||||
| 2024-09-04 | 13D/A | LQDA / Liquidia Corporation | 10,360,945 | 6,994,997 | ||||
| 2024-06-24 | 13D/A | ALIM / Alimera Sciences, Inc. | 17,635,154 | 17,635,154 | ||||
| 2024-05-30 | 13D/A | ANIK / Anika Therapeutics, Inc. | 1,423,493 | 1,435,993 | ||||
| 2024-03-06 | 13D/A | ANIK / Anika Therapeutics, Inc. | 1,081,360 | 1,423,493 | ||||
| 2024-01-08 | 13D/A | LAB / Standard BioTools Inc. | 7,797,454 | 7,042,413 | ||||
| 2023-12-14 | 13D/A | LQDA / Liquidia Corporation | 7,167,663 | 10,360,945 | ||||
| 2023-09-11 | 13D/A | ANIK / Anika Therapeutics, Inc. | 902,086 | 1,081,360 | ||||
| 2023-08-17 | 13D | ANIK / Anika Therapeutics, Inc. | 902,086 | |||||
| 2023-08-03 | 13D/A | ALIM / Alimera Sciences, Inc. | 915,057,915,057 | 17,635,154 | ||||
| 2023-07-03 | 13D/A | LAB / Standard BioTools Inc. | 8,576,799 | 7,797,454 | ||||
| 2023-06-02 | 13D/A | EXEL / Exelixis, Inc. | 850,000 | 910,730 | ||||
| 2023-05-18 | 13D/A | ALIM / Alimera Sciences, Inc. | 724,716 | 915,057,915,057 | ||||
| 2023-03-28 | 13D/A | ALIM / Alimera Sciences, Inc. | 411,527 | 724,716 | ||||
| 2023-03-27 | 13D/A | EXEL / Exelixis, Inc. | 850,000 | 850,000 | ||||
| 2023-03-20 | 13D | EXEL / Exelixis, Inc. | 850,000 | |||||
| 2022-12-30 | 13D/A | LAB / Standard BioTools Inc. | 11,444,836 | 8,576,799 | ||||
| 2022-12-09 | 13D/A | ADMA / ADMA Biologics, Inc. | 10,893,237 | 10,264,311 | ||||
| 2022-08-05 | 13D/A | LAB / Standard BioTools Inc. | 10,423,188 | 11,444,836 | ||||
| 2022-06-07 | 13D/A | LAB / Standard BioTools Inc. | 9,484,838 | 10,423,188 | ||||
| 2022-05-25 | 13D | ALIM / Alimera Sciences, Inc. | 411,527 | |||||
| 2022-05-03 | 13D/A | FLDM / Standard BioTools Inc | 8,380,265 | 9,484,838 | ||||
| 2022-03-29 | 13D/A | FLDM / Standard BioTools Inc | 8,380,265 | 8,380,265 | ||||
| 2022-02-04 | 13D | ADMA / ADMA Biologics, Inc. | 10,893,237 | |||||
| 2021-12-07 | 13D/A | LQDA / Liquidia Corporation | 8,328,418 | 7,167,663 | ||||
| 2021-05-10 | 13D | FLDM / Standard BioTools Inc | 8,380,265 | |||||
| 2021-04-15 | 13D | LQDA / Liquidia Corporation | 8,328,418 | |||||
| 2020-11-16 | 13D/A | US00163U1060 / AMAG Pharmaceuticals, Inc. | 3,519,287 | 0 | ||||
| 2019-10-10 | 13D/A | US00163U1060 / AMAG Pharmaceuticals, Inc. | 3,499,428 | 3,519,287 | ||||
| 2019-09-30 | 13D/A | KN / Knowles Corporation | 4,621,578 | 4,316,236 | ||||
| 2019-09-04 | 13D/A | US00163U1060 / AMAG Pharmaceuticals, Inc. | 3,499,428 | 3,499,428 | ||||
| 2019-08-15 | 13D | US00163U1060 / AMAG Pharmaceuticals, Inc. | 3,499,428 | |||||
| 2019-05-09 | 13D/A | KN / Knowles Corporation | 4,045,343 | 4,621,578 | ||||
| 2019-03-11 | 13D | KN / Knowles Corporation | 4,045,343 |
